This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Chiesi Farmaceutici S.p.A.
Drug Names(s): zileuton IR (immediate release) tablets
All historical revenue for Zyflo IR and Zyflo CR is recorded under Zyflo IR.
Zileuton is an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid.
Critical Therapeutics and Abbott
In March 2004, Critical Therapeutics (CT) acquired from Abbott the U.S. trademark Zyflo and an exclusive worldwide license, to develop, make, use and sell the immediate-release formulation of zileuton for all clinical indications. In consideration for the license and the trademark, CT agreed to pay Abbott an initial fee of $500,000, a milestone payment of $750,000 upon approval of the sNDA, and royalties based upon net sales of licensed products by CT. CT's obligation to pay royalties continues on a country-by-country basis for a period of ten years from the first commercial sale of a licensed product in each country.
Critical Therapeutics and DEY
In March 2007, CT and DEY, an affiliate of Merck KGaA, signed a definitive co-promotion agreement for Zyflo. DEY and CT have agreed to jointly promote Zyflo IR (zileuton tablets) and Zyflor CR (controlled release zileuton), pending regulatory approval by the U.S. Food and Drug...See full deal structure in Biomedtracker
Partners: AbbVie Inc. Mylan Inc.
Zyflo IR News
Pink Sheet First-line indication for Avalide
Additional information available to subscribers only: